Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Breast ECM stiffness - CA1a cells

ABSTRACT: Comparision of CA1a cells grown in normal breast tissue pressure (NBP, 140 Pa) and breast tumor tissue pressure (BTP, 5000 Pa). Both conditions cultured in triplicates and quantified using TMT 6plex. TMT 126-128 - NBP TMT 129-131 - BTP

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Janne Lehtiö

PROVIDER: PXD030965 | JPOST Repository | Fri Nov 15 00:00:00 GMT 2024

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	HJ_SSSG_BC-CA1a_1-6_TMT_100ug_IPG37-49_fr16.raw	Raw
	HJ_SSSG_BC-CA1a_1-6_TMT_100ug_IPG37-49_fr17.raw	Raw
	HJ_SSSG_BC-CA1a_1-6_TMT_100ug_IPG37-49_fr18.raw	Raw
	HJ_SSSG_BC-CA1a_1-6_TMT_100ug_IPG37-49_fr19.raw	Raw
	HJ_SSSG_BC-CA1a_1-6_TMT_100ug_IPG37-49_fr20.raw	Raw

Items per page:

1 - 5 of 20

Similar Datasets

Analysis of sectreted proteins from breast cancer cells

Project description:Analysis of sectreted proteins from pure media, LX and Heps breast cancer cells grown in conditioned media. All samples were prepared in biological triplicates.

2021-06-28 | PXD015426 | Pride

HiRIEFII proteomics and proteogenomics of A431 cells and five histologically normal tissues

Project description:High Resolution Isoelectric Focusing (HiRIEF) LC-MS was used to analyze samples from the human A431 cell line and also samples of histologically normal tissues. The high analytical depth afforded by HiRIEF permitted proteogenomics on these two sample sets (A431 cells and normal tissues). The A431 data was obtained from a time course experiment upon Gefitinib treatment (EGFR inhibition) of A431 cells with harvests at 2h, 6h and 24h after treatment as well of untreated cells. Isobaric tag labelling of peptide samples with TMT10plex was used. Biological triplicate controls (TMT channels 126, 127N, 127C), duplicate 2h (128N, 128C), duplicate 6h (129N, 129C) and triplicate 24h (130N, 130C, 131) samples were employed. The normal tissues data was obtained from two separate TMT10plex sets. TMT set1 was composed of 9 samples, all from different individuals, including three placenta samples (126, 127N, 127C) two liver samples (128N, 128C), two kidney samples (129N, 129C), two tonsil samples (130N, 130C), plus an internal pooled standard (131). TMT set2 was composed of 8 samples, all from different individuals, including one tonsil sample (126), two liver samples (127C, 128N), two kidney samples (128C, 129N), three testis samples (129C, 130N, 130C), plus an internal pooled standard (131). The internal pooled standard was made by combining equal aliquots of the tryptic peptide mixtures from each of the 17 tissue samples.

2018-01-19 | PXD006291 | Pride

RTNs and DP1 Knockdown in neurons

Project description:Quantitative proteomics results of RTNs-KD neurons or DP1-KD neurons (DIV5). Peptides derived from Untreated neurons (UNT) were chemically labeled with TMT-126, pSuper-neurons with TMT-127, shRNAs_RTNs-neurons with TMT-128 and shRNA_DP1-neurons with TMT-131.

2019-02-15 | PXD012264 | Pride

Proteome expression changes upon Halofuginone treatment

Project description:NHCF-V primary cardiac fibroblasts where treated for 24 hours with either 1) 100nM Halofuginone (TMT labels 126 and 129L) 2) 300nM Halofuginone (TMT labels 127L and 129H) 3) 300 nM Halofuginone + 4 mM L-Pro (TMT labels 127H and 130L) 4) DMSO (TMT labels 128H and 131)

2017-05-16 | PXD005679 | Pride

Immediate adaption – Quantitative Proteomics of BCL6 silencing and EGFR TK inhibition

Project description:We aimed to identify the response mechanism to EGFR tyrosine kinase inhibition. A431 cells were transfected with mock siRNA or BCL6 siRNA. Cells were then treated with gefitinib. Harvesting was done at 0h, at 24h and at 48h. Two TMT10plex sets were organized as follows: TMT set1: mock 0h (3x, channels 126, 127N and 127C), mock 24h (3x, 128N, 128C and 129N), mock 48h (3x, 129C, 130N, 130C) and internal pooled standard (131) composed from equal aliquots of all samples (mock siRNA and BCL6 siRNA). TMT set2: siBCL6 0h (3x, channels 126, 127N and 127C), siBCL6 24h (3x, 128N, 128C and 129N), siBCL6 48h (3x, 129C, 130N, 130C) and the same internal pooled standard (131) as for set 1.

2020-12-09 | PXD016605 | Pride

rat myocardial left ventricular tissue proteins LC-MSMS

Project description:Rat left ventricular tissue LC-MSMS.Rat left ventricular tissue proteins from different groups were extracted and quantified using the BCA Protein Assay Kit (Thermo Fisher Scientific, USA). The proteins were then labeled with tandem mass tags (TMT). TMT6/10 (Pierce, USA) with different reporter ions (126-131 Da) were applied as isobaric tags for relative quantification. Then the labeled peptide aliquots were combined for fractionation and further LC-MS analysis. The LC–MS/MS analysis was carried out in Capitbalbio Technology by using Q Exactive mass spectrometer (Thermo Fisher Scientific, USA). Twenty most intense precursor ions from a survey scan were selected for MS/MS detected in Orbitrap analyser. All the tandem mass spectra were produced by higher-energy collision dissociation (HCD) method. The MS/MS data was collected and searched against the Oryctolagus cuniculus database using the Sequest algorithms. A protein with fold change≥1.5, and the presence of least 2 unique peptides with a P value <0.05, was considered to be differentially expressed protein (DEP). Finally, DEPs were analyzed by reference to three key databases: Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome and the Clusters of Orthologous Groups (COG).

2021-07-26 | PXD024641 | Pride

Proteome characterization of Breast Cancer Cell lines

Project description:Protein profiling of 18 breast cancer cell lines in triplicates using TMT10-plex.

2020-07-04 | PXD013276 | JPOST Repository

MicroRNA expression profiling of tamoxifen sensitive and resistant ER+ breast cancer cell lines

Project description:Tamoxifen is an effective anti-estrogen treatment for patients with estrogen receptor-positive (ER+) breast cancer. However, about 30% of such patients receiving tamoxifen as an adjuvant therapy experience recurrence within 15 years, and most patients with advanced disease eventually develop resistance to tamoxifen. To elucidate the underlying molecular mechanisms of tamoxifen resistance, we performed a systematic analysis of miRNA-mediated gene regulation in three clinically-relevant tamoxifen-resistant human breast cancer cell lines (TamRs) compared to their parental tamoxifen-sensitive MCF-7/S0.5 cell line. Alterations in the expression of 131 miRNAs in tamoxifen-resistant vs. parental cell lines were identified, 22 of which were common to all TamRs using both sequencing and LNA-based quantitative PCR technologies. ER+ and tamoxifen sensitive breast cancer cell line (MCF-7/S0.5) and its derived tamoxifen resistant clones: TAMR-1, TAMR-4 and TAMR-8 were miRNA expression profiled in triplicates of each using Exiqon's miRCURY LNA based microRNA Ready-to-use PCR, Human panel I+II, V2.R (Exiqon, product number 203608).

2015-08-01 | E-GEOD-56411 | biostudies-arrayexpress

HiRIEF-LC-MS based proteomics on Small Intestinal Neuroendocrine Tumors (SI-NET) and SI-NET cell lines

Project description:Associated to PXD009877 which contains Part I and Part II. Part III – Pevonedistat/MLN4924 and Bortezomib treatment of the SI-NET (small intestinal – neuroendocrine tumor) cell line CNDT2. High Resolution Isoelectric Focusing (HiRIEF) LC-MS and relative quantification by TMT 10-plex was used to analyze cellular response to the proteasome inhibitor Bortezomib alone or in combination with the neddylation inhibitor pevonedistat (MLN4924) at 12h after treatment in the CNDT2 cell line. The data was obtained from one TMT 10-plex experiment which included 4 untreated controls (TMT channels 126, 127N, 127C and 128N), 3 samples treated with 500 nM Bortezomib for 12 hours (TMT channels 128C, 129N and 129C) as well as 3 samples treated with both Bortezomib and Pevonedistat at 500 nM respectively for 12 hours (TMT channels 130N, 130C and 131).

2021-06-10 | PXD013024 | Pride

HiRIEFII proteomics and proteogenomics of A431 cells and five histologically normal tissues

2018-10-04 | MSV000083000 | MassIVE